Indicators of oxidative stress and the effect of antioxidant treatment in patients with primary Parkinson's disease;Indicadores de estres oxidativo y efecto del tratamiento antioxidante en pacientes con enfermedad de Parkinson primaria

Revista de Neurologia

Volumn 26, Issue 149, 1998, Pages 28-33

  Gonzalez Fraguela M E ^a  

^a REN   (Cuba)

Author keywords

Antioxidants; Catalase; Malonyl aldehyde; Parkinson's disease; Phospholipase A2; Vitamin C

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CATALASE; LEVODOPA; MALONALDEHYDE; MONOAMINE OXIDASE INHIBITOR; PHOSPHOLIPASE A2; ANTIOXIDANT; BIOLOGICAL MARKER; PHOSPHOLIPASE A; REACTIVE OXYGEN METABOLITE;

ARTICLE; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; ENZYMOLOGY; METABOLISM; METHODOLOGY; SPECTROPHOTOMETRY;

ANTIOXIDANTS; ASCORBIC ACID; BIOLOGICAL MARKERS; CATALASE; DISEASE PROGRESSION; HUMANS; MALONDIALDEHYDE; MONOAMINE OXIDASE INHIBITORS; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHOLIPASES A; REACTIVE OXYGEN SPECIES; SPECTROPHOTOMETRY; VITAMIN E;

EID: 0031594709     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.26149.981077     Document Type: Article

References (4)

1. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992; 32: 2-9.
2. Coyle JT, Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorders. Science 1992; 262: 689-94.
3. Hirsh EC. Why are nigral catecholaminergic neurons more vulnerable than other cell in Parkinson's disease? Ann Neurol 1992; 32: 88-93.
4. Damier P, et al. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993; 52: 1-6.